Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.

NCT00504933 is registered in ClinicalTrials.gov with Faes Farma, S.A. as lead sponsor.

NCT NCT00504933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.
Lead sponsor
Faes Farma, S.A.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2005
Enrollment
683 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis